Human pharmacogenomic variation of antihypertensive drugs: From population genetics to personalized medicine

Pharmacogenomics

Volumn 15, Issue 2, 2014, Pages 157-167

  Polimanti, Renato ^a   Iorio, Andrea ^b   Piacentini, Sara ^a   Manfellotto, Dario ^b   Fuciarelli, Maria ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

bioinformatics; blood pressure; drugs; geographic origin; hypertension; pharmacogenomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BEPRIDIL; DILTIAZEM; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; MIBEFRADIL; TELMISARTAN; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG RESPONSE; ETHNICITY; GENE; GENE FUNCTION; GENETIC VARIABILITY; GEOGRAPHY; HUMAN; HYPERTENSION; PERSONALIZED MEDICINE; PHARMACOGENE; PHARMACOGENOMICS; POPULATION DIFFERENTIATION; POPULATION GENETICS; PREDICTION; COMPUTER SIMULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIHYPERTENSIVE AGENTS; COMPUTER SIMULATION; GENETICS, POPULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84893077203     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.231     Document Type: Article

References (50)

1. Johnson JA. Pharmacogenomics of antihypertensive drugs: Past, present and future. Pharmacogenomics 11(4), 487-491 (2010).
2. Arnett DK, Baird AE, Barkley RA et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: A scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115(22), 2878-2901 (2007).
3. Citterio L, Lanzani C, Manunta P. Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics 12(11), 1587-1604 (2011).
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 365(9455), 217-223 (2005).
5. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann. Med. 44(Suppl. 1), S17-S22 (2012).
6. Chobanian AV. Shattuck Lecture. The hypertension paradox-more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361(9), 878-887 (2009).
7. Parati G, Omboni S, Compare A et al. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: Protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). Trials 14, 22 (2013).
8. Gong Y, McDonough CW, Wang Z et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study. Circ. Cardiovasc. Genet. 5(6), 686-691 (2012).
9. McDonough CW, Burbage SE, Duarte JD et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J. Hypertens. 31(4), 698-704 (2013).
10. Kamide K, Kawano Y, Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertens. Res. 35(8), 796-799 (2012).
11. Marian AJ. Molecular genetic studies of complex phenotypes. Transl. Res. 159(2), 64-79 (2012).
12. Henson J, Tischler G, Ning Z. Next-generation sequencing and large genome assemblies. Pharmacogenomics 13(8), 901-915 (2012).
13. Vanakker OM, De Paepe A. Pharmacogenomics in children: Advantages and challenges of next generation sequencing applications. Int. J. Pediatr. 2013, 136524 (2013).
14. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: Towards individualized pharmaceutical treatment. J. Natl Med. Assoc. 94(Suppl. 10), S1-S26 (2002).
15. Johnson JA. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 118(13), 1383-1393 (2008).
16. Li JZ, Absher DM, Tang H et al. Worldwide human relationships inferred from genome-wide patterns of variation. Science 319(5866), 1100-1104 (2008).
17. International Hapmap 3 Consortium, Altshuler DM, Gibbs RA et al. Integrating common and rare genetic variation in diverse human populations. Nature 467(7311), 52-58 (2010).
18. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D et al. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010).
19. Polimanti R, Piacentini S, Manfellotto D, Fuciarelli M. Human genetic variation of CYP450 superfamily: Analysis of functional diversity in worldwide populations. Pharmacogenomics 13(16), 1951-1960 (2012).
20. Polimanti R, Fuciarelli M, DestroBisol G, Battaggia C. Functional diversity of glutathione peroxidase gene family among human populations: Implications for genetic predisposition to disease and drug response. Pharmacogenomics 14(9), 1037-1045 (2013).
21. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11(4), 501-505 (2010).
22. Franceschini A, Szklarczyk D, Frankild S et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41(Database issue), D808-D815 (2013).
23. Licata L, Briganti L, Peluso D et al. MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 40(Database issue), D857-D861 (2012).
24. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27-30 (2000).
25. Excoffier L, Lischer HE. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 10(3), 564-567 (2010).
26. Excoffier L, Hofer T, Foll M. Detecting loci under selection in a hierarchically structured population. Heredity 103(4), 285-298 (2009).
27. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 155(2), 945-959 (2000).
28. Rosemberg NA. DISTRUCT: A program for the graphical display of population structure. Mol. Ecol. Notes 4, 137-138 (2004).
29. Hofer T, Ray N, Wegmann D, Excoffier L. Large allele frequency differences between human continental groups are more likely to have occurred by drift during range expansions than by selection. Ann. Hum. Genet. 73(1), 95-108 (2009).
30. Travis JM, Munkemuller T, Burton OJ, Best A, Dytham C, Johst K. Deleterious mutations can surf to high densities on the wave front of an expanding population. Mol. Biol. Evol. 24(10), 2334-2343 (2007).
31. Bryc K, Auton A, Nelson MR et al. Genomewide patterns of population structure and admixture in west Africans and African Americans. Proc. Natl Acad. Sci. USA 107(2), 786-791 (2010).
32. Gupta AK, Poulter NR, Dobson J et al. Ethnic differences in blood pressure response to first and secondline antihypertensive therapies in patients randomized in the ASCOT Trial. Am. J. Hypertens. 23(9), 1023-1030 (2010).
33. Wikoff WR, Frye RF, Zhu H et al. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS ONE 8(3), e57639 (2013).
34. Ofili EO, Ferdinand KC, Saunders E et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J. Natl Med. Assoc. 98(4), 618-626 (2006).
35. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitorassociated angioedema. Clin. Pharmacol. Ther. 60(1), 8-13 (1996).
36. Elliott WJ, Ram CV. Calcium channel blockers. J. Clin. Hypertens. (Greenwich) 13(9), 687-689 (2011).
37. Maitlandvan der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am. J. Hypertens. 18(8), 1077-1083 (2005).
38. Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).
39. Albert MA, Glynn RJ, Fonseca FA et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am. Heart J. 162(1), 106-114.e2 (2011).
40. Squitti R, Polimanti R. Copper hypothesis in the missing hereditability of sporadic Alzheimer's disease: ATP7B gene as potential harbor of rare variants. J. Alzheimers Dis. 29(3), 493-501 (2012).
41. Nelson MR, Wegmann D, Ehm MG et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337(6090), 100-104 (2012).
42. Lobmeyer MT, Wang L, Zineh I et al. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensivetreated patients. Pharmacogenet. Genomics 21(1), 42-49 (2011).
43. Liljedahl U, Karlsson J, Melhus H et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 13(1), 7-17 (2003).
44. Roszer T, Ricote M. PPARs in the renal regulation of systemic blood pressure. PPAR Res. 2010, 698730 (2010).
45. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J. 2(5), 309-317 (2002).
46. Siest G, Jeannesson E, VisvikisSiest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin. Chim. Acta 381(1), 26-31 (2007).
47. Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics 10(3), 477-487 (2009).
48. Turner ST, Bailey KR, Fridley BL et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52(2), 359-365 (2008).
49. Niu Y, Gong Y, Langaee TY et al. Genetic variation in the beta2 subunit of the voltagegated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SRTrandolapril STudy GENEtic Substudy (INVESTGENES). Circ. Cardiovasc. Genet. 3(6), 548-555 (2010).
50. Polasek TM, Elliot DJ, Lewis BC, Miners JO. Mechanismbased inactivation of human cytochrome P4502C8 by drugs in vitro. J. Pharmacol. Exp. Ther. 311(3), 996-1007 (2004).